Stock Events

Stock Events

Biofrontera 

€0.3240
59
-€0.02-5.26% Monday 15:30

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.62
-0.42
-0.22
-0.03
Expected EPS
N/A
Actual EPS
N/A

Financials

-59.57%Profit Margin
Unprofitable
2020
2021
2022
2023
31.37MRevenue
-18.69MNet Income

Analyst Ratings

2.28Average Price Target
The highest estimate is 2.28.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Davis Select U.S. Equity
DUSA
Mkt Cap0
DUSA Pharmaceuticals, Inc. is a direct competitor in the dermatology space, specifically in photodynamic therapy products, similar to Biofrontera's Ameluz for treating actinic keratosis.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a diversified portfolio that includes treatments for various conditions, including skin-related diseases, potentially competing with Biofrontera's dermatological products.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a global pharmaceutical company with a broad product line that includes treatments for skin conditions, making it a competitor to Biofrontera.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson offers a wide range of healthcare products, including pharmaceuticals and personal care products for skin health, competing with Biofrontera's dermatological treatments.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc., having acquired Allergan, has strengthened its dermatology portfolio, making it a stronger competitor to Biofrontera in the skin care and treatment market.
Novartis
NVS
Mkt Cap292.35B
Novartis International AG has a significant presence in the dermatology market with products that treat a range of skin conditions, competing with Biofrontera's therapeutic offerings.

About

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin. It has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Show more...
CEO
Ms. Pilar de la Huerta Martinez
Employees
91
Country
Germany
ISIN
DE000A40ESN8
WKN
000A40ESN

Listings

XNAS
US
BFRI
MU
DE
B8FK.MU
MU
DE
AI1.MU
STU
DE
AI10.STU

0 Comments

Share your thoughts

FAQ

What is Biofrontera stock price today?▼
The current price of B8F.XETRA is €0.32 EUR — it has decreased by -5.26% in the past 24 hours. Watch Biofrontera stock price performance more closely on the chart.
What is Biofrontera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Biofrontera stocks are traded under the ticker B8F.XETRA.
What is Biofrontera revenue for the last year?▼
Biofrontera revenue for the last year amounts to 31.37M EUR.
What is Biofrontera net income for the last year?▼
B8F.XETRA net income for the last year is -18.69M EUR.
How many employees does Biofrontera have?▼
As of September 07, 2026, the company has 91 employees.
In which sector is Biofrontera located?▼
Biofrontera operates in the Health & Wellness sector.
When did Biofrontera complete a stock split?▼
The last stock split for Biofrontera was on July 05, 2023 with a ratio of 1:20.
Where is Biofrontera headquartered?▼
Biofrontera is headquartered in Leverkusen, Germany.